Comparative Pharmacology
Head-to-head clinical analysis: LASTACAFT versus OPCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LASTACAFT versus OPCON A.
LASTACAFT vs OPCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits mast cell degranulation and reduces release of inflammatory mediators.
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
1 drop in each affected eye twice daily (approximately every 8 hours)
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours; clinically, dosing is twice daily.
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment.
Renal: approximately 70% as unchanged drug; fecal: approximately 30% as metabolites.
Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine/Decongestant Combination